Haemophilus influenzae Type B Antibody, IgG, Serum
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Haemophilus influenzae type B (HIB) is an encapsulated gram-negative cocco-bacillary bacterium that can cause devastating disease in young children including meningitis, bacteremia, cellulitis, epiglottitis, pneumonia, and septic arthritis.
One of the great advances in modern medicine has been the development of an effective vaccine against HIB. A patient's immunological response to HIB vaccine can be determined by measuring anti-HIB IgG antibody using this EIA technique.
Assessing a patient's immunological (IgG) response to Haemophilus influenzae type B (HIB) vaccine
Assessing immunity against HIB
Aiding in the evaluation of immunodeficiency
An anti-Haemophilus influenzae type B (HIB) IgG antibody concentration of 0.15 mg/L is generally accepted as the minimum level for protection at a given time; however, it does not confer long-term protection. A study from Finland suggested that the optimum protective level is 1.0 mg/L postimmunization.(1) Furthermore, studies have shown that the response to HIB vaccine is age-related.
By testing pre- and postvaccination patient serum specimens, this test may be used to aid diagnosis of immunodeficiency.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
This assay does not provide diagnostic proof of the presence or absence of immune deficiency. Results must be confirmed by clinical findings and other laboratory tests.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
> or =0.15 mg/L
Clinical References Provides recommendations for further in-depth reading of a clinical nature
1. Peltola H, Kayhty H, Virtanen M, et al: Prevention of Haemophilus influenzae type B bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984;310(24):1561-1566
2. Berger M: Immunoglobulin G subclass determination in diagnosis and management of antibody deficiency syndromes. J Pediatr 1987;110(2):325-328